Journal of Medical Microbiology · 2015 · 20 citations · 30 references
Life SciencesImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyAdjuvant DevelopmentCell-mediated ImmunityCellular Immunity In InfectionConjugate VaccinesVaccine PlatformsViral VaccinesAntigen-induced Lymphocyte ProliferationBacterial Flagellin RecognitionConjugate Vaccine AdjuvantsLymphocyte Proliferation InhibitionPeptide AdjuvantsTh1 Immune ResponseVaccination AdjuvantsVaccine Candidate Antigens
In the present study, the adjuvant activity of flagellin was compared, in the conjugated and mixed forms, against a peptide vaccine from human immunodeficiency virus type 1 (HIV-1) p24-Nef vaccine candidate. Mice were immunized with the HIV-1 p24-Nef peptide with flagellin in both conjugated and mixed forms. Lymphocyte proliferation, CTL activity, and IL-4 and IFN-γ cytokines were evaluated by bromodeoxyuridine, carboxyfluorescein succinimidyl ester and ELISA methods, respectively. At the same time, the frequency of IFN-γ-producing T-lymphocytes, as well as total and isotype-specific antibodies, were assessed by ELISPOT and indirect ELISA, respectively. Our experimental results showed that the immunized mice with the HIV-1 p24-Nef conjugated or mixed forms of flagellin led to increases in the proliferative responses and Th1 cytokine pattern. The conjugated form of vaccine led to increased CTL activity and a Th1 cytokine pattern of immune responses, as well as an IgM isotype of humoral responses in comparison with the mixed form. The flagellin-conjugated vaccine seems to be more potent in increasing vaccine immunogenicity.
30
Gersende Caron, Dorothée Duluc, Isabelle Frémaux et al. · The Journal of Immunology · 2005 · 412 citations · Full text